We also assessed the KRAS/CDK1 SL in cell models of pancreatic ductal adenocarcinoma (PDAC), a disease where where somatic KRAS mutations are prevalent in approximately 90% of cases [34]. Here, CDK1 is linked to pancreatic ductal adenocarcinoma.